Head-to-head · free

SOPHiA GENETICS S.A. vs Teva Pharmaceutical Industries Limited

SOPH vs TEVA — return on capital, cash generation, margins and balance sheet side by side.

SOPH

2 / 4

measures where SOPH leads

TEVA

2 / 4

measures where TEVA leads

A simple count of which company scores better on each measure — not a recommendation to buy or sell.

MeasureSOPHTEVA · FY2025
Revenue—$1.5B
Net income—$1.4B
Revenue growth (yearly, multi-year)—-44.6%
Free cash flow——
Free cash flow margin——
Net cash / (debt)——
ROIC——
Return on equity-110.0%21.2%
Gross margin67.4%51.8%
Operating margin-91.8%22.9%
Net debt / EBITDA0.37x4.19x

Figures are as reported by each company; latest fiscal year shown.

Where SOPHiA GENETICS S.A.'s cash went

Not reported yet.

Full SOPH profile →

Where Teva Pharmaceutical Industries Limited's cash went (FY2025)

Capital spending
—
Buybacks
—
Dividends
—
Acquisitions
—
Net debt issued / (repaid)
—
Full TEVA profile →

Ask which business is stronger

"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.

Compare them free

More comparisons